Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 159

Sort by

Sort Order Select

Journal Articles

Essential thrombocythemia: challenges in clinical practice and future prospects

Anna L. Godfrey, Anna C. Green, Claire N. Harrison

Blood (2023) 141 (16): 1943–1953.

https://doi.org/10.1182/blood.2022017625

Published: 2023

Journal Articles

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood (2022) 139 (19): 2931–2941.

https://doi.org/10.1182/blood.2021012743

Published: 2022

Includes: Supplemental data

Journal Articles

Independent Prognostic Value of Flow Cytometry (FCM) in Myelodysplastic Syndromes (MDS) - Composition of a Prognostic FCM-Score for Overall Survival

Uta Oelschlaegel, Aida Santaolalla, Jessica A. Timms, Susann Winter, Katja Sockel, Martin Bornhäuser, Farzin Farzaneh, Claire N. Harrison, Theresia M. Westers, Arjan van de Loosdrecht, Mieke Van Hemelrijck, Uwe Platzbecker, Shahram Kordasti

Blood (2021) 138 (Supplement 1): 2603.

https://doi.org/10.1182/blood-2021-146367

Published: 2021

Journal Articles

Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data

Blood (2021) 138 (Supplement 1): 2568.

https://doi.org/10.1182/blood-2021-152267

Published: 2021

Journal Articles

Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly

Jean-Jacques Kiladjian, Ayalew Tefferi, Francesco Passamonti, Alessandro Vannucchi, Moshe Talpaz, Francisco Cervantes, Claire N. Harrison, Ruben A. Mesa, John Mascarenhas, Nicolaas Schaap, Srdan Verstovsek, Timothy Devos, Shelonitda Rose, Jun Zhang, Oumar Sy, Animesh Pardanani

Blood (2021) 138 (Supplement 1): 2576.

https://doi.org/10.1182/blood-2021-147618

Published: 2021

Journal Articles

Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure

Claire N. Harrison, John Mascarenhas, Pranav Abraham, Arianna Kee, Jose Alberto Nadal, Alexandrina Balanean, Ali McBride, Jonathan K. Kish, Djibril Liassou, Bruce A. Feinberg, Aaron T. Gerds

Blood (2021) 138 (Supplement 1): 3059.

https://doi.org/10.1182/blood-2021-145569

Published: 2021

Journal Articles

Second Versus First Wave of COVID-19 in Patients with MPN

Tiziano Barbui, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Greta Carioli, Marta Sobas, Elena Maria Elli, Elisa Rumi, Valerio De Stefano, Francesca Lunghi, Monia Marchetti, Rosa Daffini, Mercedes Gasior Kabat, Beatriz Cuevas, Laura Maria Fox, Marcio Andrade, Francesca Palandri, Paola Guglielmelli, Giulia Benevolo, Claire N. Harrison, Maria Angeles Foncillas, Massimiliano Bonifacio, Alberto Alvarez-Larran, Jean-Jacques Kiladjian, Estefanía Bolaños, Andrea Patriarca, Keina Quiroz, Martin Griesshammer, Valentín Garcia Gutierrez, Alberto Marin Sanchez, Elena Magro, Marco Ruggeri, Juan Carlos Hernandez Boluda, Santiago Osorio, Gonzalo Carreño Gomez-Tarragona, Miguel Sagüés, Rajko Kusec, Begoña Navas, Anna Angona, Blanca Xicoy, Emma Lopez Abadia, Steffen Koschmieder, Daniele Cattaneo, Cristina Bucelli, Edyta Cichocka, Anna Masternak, Fabrizio Cavalca, Oscar Borsani, Silvia Betti, Marta Bellini, Natalia Curto-Garcia, Alessandro Rambaldi, Alessandro Vannucchi

Blood (2021) 138 (Supplement 1): 315.

https://doi.org/10.1182/blood-2021-146134

Published: 2021

Journal Articles

'Application of Prognostic Scoring in Systemic Mastocytosis Patients within a UK Centre of Excellence: Guys and St Thomas' NHS Foundation Trust.'

Priya Sriskandarajah, Clare Oni, Claire Woodley, Susan Asirvatham, Monika Ciesielska, Chienye Asinobi, Rebecca Todd, Natalia Curto-Garcia, Jennifer O'Sullivan, Chandan Saha, Thompson Olaoni, Anna Green, Yurina Miki, Mark Ong, Donal P McLornan, Claire N. Harrison, Clive Grattan, Deepti H. Radia

Blood (2021) 138 (Supplement 1): 3625.

https://doi.org/10.1182/blood-2021-152234

Published: 2021

Journal Articles

The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study

Jeanne M. Palmer, Ruben A. Mesa, Stephen T. Oh, Raajit Rampal, Sarah A Buckley, Karisse Roman-Torres, Srdan Verstovsek, John Mascarenhas, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Claire N. Harrison, Prithviraj Bose, Adam R Craig, Aaron T. Gerds

Blood (2021) 138 (Supplement 1): 3628.

https://doi.org/10.1182/blood-2021-144505

Published: 2021

Journal Articles

Long-Term Treatment with Pacritinib on a Compassionate Use Basis in Patients with Advanced Myelofibrosis

Claire N. Harrison, Abdulraheem Yacoub, Bart L. Scott, Adam J. Mead, Aaron T. Gerds, Jean-Jacques Kiladjian, Ruben A. Mesa, Miklos Egyed, Christof Scheid, Valentín Garcia Gutierrez, Sarah A Buckley, Kris Kanellopoulos, John Mascarenhas

Blood (2021) 138 (Supplement 1): 3649.

https://doi.org/10.1182/blood-2021-148793

Published: 2021

Journal Articles

Safety Analysis of Pacritinib in Patients with Myelofibrosis and Severe Thrombocytopenia

John Mascarenhas, Claire N. Harrison, Aaron T. Gerds, Josef T. Prchal, Raajit Rampal, Sarah A Buckley, Adam R Craig, Jennifer A. Smith, John Volpone, Karisse Roman-Torres, Ruben A. Mesa

Blood (2021) 138 (Supplement 1): 3640.

https://doi.org/10.1182/blood-2021-151395

Published: 2021

Journal Articles

Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study

Steffen Koschmieder, Clemens Schulte, Eyck von der Heyde, Lambert Busque, Françoise Boyer-Perrard, Timothy Devos, Francesco Passamonti, Mike W. Zuurman, Carole Paley, Geralyn Gilotti, Wendy Y. Cheng, Chi Gao, Mu Cheng, Melody Wu, Mei Sheng Duh, Claire N. Harrison

Blood (2021) 138 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2021-148254

Published: 2021

Journal Articles

Correlation of Quality of Life between Treatment Outcomes in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Polycythemia Vera

Isaak Ailts, Carolyn Mead-Harvey, Adam J. Mead, Sonia Fox, Rebecca H. Boucher, Christina Yap, Chandan Saha, Robyn Scherber, Aimee Jackson, Joanne Ewing, Jason Coppell, Steve Knapper, Mark W. Drummond, Anna L Godfrey, Amylou C. Dueck, Mary Frances McMullin, Ruben A. Mesa, Claire N. Harrison, Holly L. Geyer

Blood (2021) 138 (Supplement 1): 3644.

https://doi.org/10.1182/blood-2021-147637

Published: 2021

Journal Articles

A Retrospective Head-to-Head Comparison between Pacritinib and Ruxolitinib in Patients with Myelofibrosis and Moderate to Severe Thrombocytopenia

John Mascarenhas, Prithviraj Bose, Jean-Jacques Kiladjian, Ruben A. Mesa, Aaron T. Gerds, Vikas Gupta, Claire N. Harrison, Abdulraheem Yacoub, Valentín Garcia Gutierrez, Alessandro M. Vannucchi, Christof Scheid, Patricia Velez Tenza, Sarah A Buckley, Karisse Roman-Torres, Stephen T. Oh, Marta Sobas, David Lavie, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 3639.

https://doi.org/10.1182/blood-2021-146675

Published: 2021

Journal Articles

Application of AI-Based Analytical Approaches for Multiplex Immunophenotyping of SF3B1 -Mutant Myelodysplastic Syndrome Subtype

Susann Winter, Jessica A. Timms, Uta Oelschlaegel, Antje Tunger, Claire N. Harrison, Desmond Choy, Marc Schmitz, Uwe Platzbecker, Shahram Kordasti

Blood (2021) 138 (Supplement 1): 1512.

https://doi.org/10.1182/blood-2021-149706

Published: 2021

Journal Articles

Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study

Chandan Saha, Carolyn Mead-Harvey, Adam J. Mead, Rebecca H. Boucher, Sonia Fox, Isaak Ailts, Christina Yap, Aimee E Jackson, Joanne Ewing, Jason Coppell, Steve Knapper, Mark W. Drummond, Anna L Godfrey, Amylou C. Dueck, Ruben A. Mesa, Robyn Scherber, Mary Frances McMullin, Holly L. Geyer, Claire N. Harrison

Blood (2021) 138 (Supplement 1): 1507.

https://doi.org/10.1182/blood-2021-151568

Published: 2021

Journal Articles

Single-Cell Multi-Omics Reveals the Genetic, Cellular and Molecular Landscape of TP53 Mutated Leukemic Transformation in MPN

Blood (2021) 138 (Supplement 1): 3.

https://doi.org/10.1182/blood-2021-150191

Published: 2021

Journal Articles

Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients

Blood (2021) 138 (Supplement 1): 3920.

https://doi.org/10.1182/blood-2021-152287

Published: 2021

Journal Articles

Immune Checkpoint Analysis of T Effectors and Regulatory T Cells in Patients with CML Reveals Increased Expression at Diagnosis and with Refractory Disease

Patrick Harrington, Richard Dillon, Deepti H. Radia, Donal P. McLornan, Claire Woodley, Susan Asirvatham, Kavita Raj, Natalia Curto-Garcia, Shahram Kordasti, Claire N. Harrison, Hugues de Lavallade

Blood (2021) 138 (Supplement 1): 2545.

https://doi.org/10.1182/blood-2021-150533

Published: 2021

Journal Articles

Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial

Blood (2021) 138 (Supplement 1): 141.

https://doi.org/10.1182/blood-2021-150172

Published: 2021

NARROW

Essential thrombocythemia: challenges in clinical practice and future prospects

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Independent Prognostic Value of Flow Cytometry (FCM) in Myelodysplastic Syndromes (MDS) - Composition of a Prognostic FCM-Score for Overall Survival

Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data

Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly

Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure

Second Versus First Wave of COVID-19 in Patients with MPN

'Application of Prognostic Scoring in Systemic Mastocytosis Patients within a UK Centre of Excellence: Guys and St Thomas' NHS Foundation Trust.'

The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study

Long-Term Treatment with Pacritinib on a Compassionate Use Basis in Patients with Advanced Myelofibrosis

Safety Analysis of Pacritinib in Patients with Myelofibrosis and Severe Thrombocytopenia

Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study

Correlation of Quality of Life between Treatment Outcomes in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Polycythemia Vera

A Retrospective Head-to-Head Comparison between Pacritinib and Ruxolitinib in Patients with Myelofibrosis and Moderate to Severe Thrombocytopenia

Application of AI-Based Analytical Approaches for Multiplex Immunophenotyping of SF3B1 -Mutant Myelodysplastic Syndrome Subtype

Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study

Single-Cell Multi-Omics Reveals the Genetic, Cellular and Molecular Landscape of TP53 Mutated Leukemic Transformation in MPN

Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients

Immune Checkpoint Analysis of T Effectors and Regulatory T Cells in Patients with CML Reveals Increased Expression at Diagnosis and with Refractory Disease

Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only